Roth Capital's analyst, Boobalan Pachaiyappan, has begun coverage of PolyPid (PYPD, Financial) by assigning a Buy rating and setting a price target of $9. The analyst's positive outlook on the stock is largely attributed to the promising role of D-PLEX100 in minimizing surgical site infections, especially for patients undergoing colorectal cancer surgeries.
While PolyPid’s cash reserves and the possibility of short-term dilution pose challenges, the anticipated filing of a new drug application for D-PLEX100 in the first half of 2026 might counterbalance these concerns. Additionally, the product's projected sales could exceed $800 million by 2035, providing further optimism for investors.
